Résultats de la recherche - Paul C Langley

Abandoning Eugenics and the QALY par Paul C Langley

Connect to this object online.

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma par Paul C Langley

Connect to this object online.

Imaginary Worlds and the Institute for Clinical and Economic Review (ICER) Evidence Report: Targeted Immune Modulators for Rheumatoid Arthritis par Paul C Langley

Connect to this object online.

Nullius in verba: The University of Minnesota Social and Administrative Pharmacy Program proposed Guidelines for Formulary Evaluations par Paul C Langley

Connect to this object online.

Sunlit Uplands: The Genius of the NICE Reference Case par Paul C Langley

Connect to this object online.

A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content par Paul C Langley

Connect to this object online.

Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure par Paul C Langley

Connect to this object online.

Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM) par Paul C Langley

Connect to this object online.

True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for Health Technology Assessment par Paul C Langley

Connect to this object online.

HAS Should Not Be NICE: Rejecting Imaginary Worlds in the French Technology Assessment Guidelines par Paul C Langley

Connect to this object online.

Nullius in verba: Version 2.0 of the University of Minnesota, School of Social and Administrative Pharmacy Program, Proposed Guidelines for Formulary Evaluation par Paul C Langley

Connect to this object online.

Potentially Actionable Targets: Evidence Standards for Credible Next Generation Sequencing Technology Assessment Claims par Paul C Langley

Connect to this object online.

Supporting Formulary Decisions: The Discovery of New Facts or Constructed Evidence? par Paul C Langley

Connect to this object online.

He Ao Pohewa: The PHARMAC Prescription for Pharmacoeconomic Analysis in New Zealand and the Standards of Normal Science par Paul C Langley

Connect to this object online.

Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) par Paul C Langley

Connect to this object online.

Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions par Paul C Langley

Connect to this object online.

Imaginary Worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 2015 par Paul C Langley

Connect to this object online.

Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and Economic Review (ICER) par Paul C Langley

Connect to this object online.

Intelligent Design and Imaginary Worlds in Cost-Effectiveness Claims: An Overview of Commentaries in INNOVATIONS in Pharmacy from July 2016 to February 2017 par Paul C Langley

Connect to this object online.

Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review par Paul C Langley

Connect to this object online.